524 related articles for article (PubMed ID: 35922812)
1. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
3. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
Cancer Metastasis Rev; 2021 Sep; 40(3):819-835. PubMed ID: 34499267
[TBL] [Abstract][Full Text] [Related]
6. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
Hyun S; Shin D
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
[TBL] [Abstract][Full Text] [Related]
7. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W
Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752
[TBL] [Abstract][Full Text] [Related]
8. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
9. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
11. Annual review of KRAS inhibitors in 2022.
Wang H; Chi L; Yu F; Dai H; Gao C; Si X; Wang Z; Liu L; Zheng J; Shan L; Liu H; Zhang Q
Eur J Med Chem; 2023 Mar; 249():115124. PubMed ID: 36680986
[TBL] [Abstract][Full Text] [Related]
12. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
13. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
14. Therapeutics Targeting Mutant KRAS.
Thein KZ; Biter AB; Hong DS
Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
[TBL] [Abstract][Full Text] [Related]
15. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
16. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
[TBL] [Abstract][Full Text] [Related]
18. Targeting
Zhao MH; Wu AW
Gastroenterol Rep (Oxf); 2023; 11():goac083. PubMed ID: 36632627
[TBL] [Abstract][Full Text] [Related]
19. Searching for treatments for non-G12C-KRAS mutant cancers.
Guo C; Banerji U
Br J Cancer; 2021 Aug; 125(5):625-626. PubMed ID: 33859342
[TBL] [Abstract][Full Text] [Related]
20. Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M; Barbacid M
Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
